Review



nb7516  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Novus Biologicals nb7516
    Nb7516, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pmc10239716-202-32-33?v=Novus+Biologicals
    Average 90 stars, based on 6 article reviews
    nb7516 - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    90
    Bio-Techne corporation goat anti-mouse igg2a heavy chain secondary antibody [hrp]
    Goat Anti Mouse Igg2a Heavy Chain Secondary Antibody [Hrp], supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/bio-techne+corporation___nb7516?v=Bio-Techne+corporation
    Average 90 stars, based on 1 article reviews
    goat anti-mouse igg2a heavy chain secondary antibody [hrp] - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals nb7516
    Nb7516, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pmc10239716-202-32-33?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    nb7516 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals goat anti-mouse igg2a nb7516
    Goat Anti Mouse Igg2a Nb7516, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pm37218551-88-13-17?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    goat anti-mouse igg2a nb7516 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    92
    Novus Biologicals anti mouse igg2a nb7516
    Anti Mouse Igg2a Nb7516, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pm37218551-88-14-17?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    anti mouse igg2a nb7516 - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    92
    Novus Biologicals igg2a
    ( A – C ) BALB/c mice were subjected to LPD or ID delivery of OVA or ID delivery of OVA into AFL-treated skin, or IM delivery of OVA in the presence of Alum adjuvant (Alum/IM). Serum anti-OVA IgG ( A ) and subtype IgG1 ( B ) and <t>IgG2a</t> antibody titers ( C ) were measured 3 weeks later. ( D – F ) BALB/c mice were subjected to LPD or ID delivery of 0.15 μg pdm09 vaccine or left nonimmunized (NI). Serum hemagglutination inhibition (HI) titer was measured 3 weeks later ( D ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( E ) and survival ( F ) were monitored daily for 14 days. ( G – I ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine or left NI. Serum HI titer was measured 3 weeks later ( G ). Mice were then challenged with 10× LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( H ) and survival ( I ) were monitored daily for 14 days. ( J – L ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine, or IM delivery of pdm09 vaccine in the presence of Alum adjuvant (Alum/IM), or left nonimmunized (NI). Serum HI titer was measured 3 weeks later ( J ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses, and percentage of body weight loss ( K ) and survival ( L ) were similarly monitored daily for 14 days. n = 8–9 in A – C , n = 5–10 in D – F , n = 5 in G – I , and n = 8 in J – L . One-way ANOVA with Newman-Keuls multiple-comparison test was used to compare differences between groups ( A – D , G , and J ). Log-rank test with Bonferroni’s correction was used to compare differences of survival between LPD and ID groups ( F , I , and L ). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
    Igg2a, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pmc08119203-321-28-30?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    igg2a - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    92
    Novus Biologicals goat anti mouse igg2a hrp conjugated antibody
    ( A – C ) BALB/c mice were subjected to LPD or ID delivery of OVA or ID delivery of OVA into AFL-treated skin, or IM delivery of OVA in the presence of Alum adjuvant (Alum/IM). Serum anti-OVA IgG ( A ) and subtype IgG1 ( B ) and <t>IgG2a</t> antibody titers ( C ) were measured 3 weeks later. ( D – F ) BALB/c mice were subjected to LPD or ID delivery of 0.15 μg pdm09 vaccine or left nonimmunized (NI). Serum hemagglutination inhibition (HI) titer was measured 3 weeks later ( D ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( E ) and survival ( F ) were monitored daily for 14 days. ( G – I ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine or left NI. Serum HI titer was measured 3 weeks later ( G ). Mice were then challenged with 10× LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( H ) and survival ( I ) were monitored daily for 14 days. ( J – L ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine, or IM delivery of pdm09 vaccine in the presence of Alum adjuvant (Alum/IM), or left nonimmunized (NI). Serum HI titer was measured 3 weeks later ( J ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses, and percentage of body weight loss ( K ) and survival ( L ) were similarly monitored daily for 14 days. n = 8–9 in A – C , n = 5–10 in D – F , n = 5 in G – I , and n = 8 in J – L . One-way ANOVA with Newman-Keuls multiple-comparison test was used to compare differences between groups ( A – D , G , and J ). Log-rank test with Bonferroni’s correction was used to compare differences of survival between LPD and ID groups ( F , I , and L ). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
    Goat Anti Mouse Igg2a Hrp Conjugated Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nb7516/pm27816054-93-6-13?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    goat anti mouse igg2a hrp conjugated antibody - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    ( A – C ) BALB/c mice were subjected to LPD or ID delivery of OVA or ID delivery of OVA into AFL-treated skin, or IM delivery of OVA in the presence of Alum adjuvant (Alum/IM). Serum anti-OVA IgG ( A ) and subtype IgG1 ( B ) and IgG2a antibody titers ( C ) were measured 3 weeks later. ( D – F ) BALB/c mice were subjected to LPD or ID delivery of 0.15 μg pdm09 vaccine or left nonimmunized (NI). Serum hemagglutination inhibition (HI) titer was measured 3 weeks later ( D ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( E ) and survival ( F ) were monitored daily for 14 days. ( G – I ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine or left NI. Serum HI titer was measured 3 weeks later ( G ). Mice were then challenged with 10× LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( H ) and survival ( I ) were monitored daily for 14 days. ( J – L ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine, or IM delivery of pdm09 vaccine in the presence of Alum adjuvant (Alum/IM), or left nonimmunized (NI). Serum HI titer was measured 3 weeks later ( J ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses, and percentage of body weight loss ( K ) and survival ( L ) were similarly monitored daily for 14 days. n = 8–9 in A – C , n = 5–10 in D – F , n = 5 in G – I , and n = 8 in J – L . One-way ANOVA with Newman-Keuls multiple-comparison test was used to compare differences between groups ( A – D , G , and J ). Log-rank test with Bonferroni’s correction was used to compare differences of survival between LPD and ID groups ( F , I , and L ). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

    Journal: JCI Insight

    Article Title: Vaccine delivery alerts innate immune systems for more immunogenic vaccination

    doi: 10.1172/jci.insight.144627

    Figure Lengend Snippet: ( A – C ) BALB/c mice were subjected to LPD or ID delivery of OVA or ID delivery of OVA into AFL-treated skin, or IM delivery of OVA in the presence of Alum adjuvant (Alum/IM). Serum anti-OVA IgG ( A ) and subtype IgG1 ( B ) and IgG2a antibody titers ( C ) were measured 3 weeks later. ( D – F ) BALB/c mice were subjected to LPD or ID delivery of 0.15 μg pdm09 vaccine or left nonimmunized (NI). Serum hemagglutination inhibition (HI) titer was measured 3 weeks later ( D ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( E ) and survival ( F ) were monitored daily for 14 days. ( G – I ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine or left NI. Serum HI titer was measured 3 weeks later ( G ). Mice were then challenged with 10× LD 50 of mouse-adapted pdm09 viruses. Percentage of body weight loss ( H ) and survival ( I ) were monitored daily for 14 days. ( J – L ) C57BL/6 mice were subjected to LPD or ID delivery of pdm09 vaccine, or IM delivery of pdm09 vaccine in the presence of Alum adjuvant (Alum/IM), or left nonimmunized (NI). Serum HI titer was measured 3 weeks later ( J ). Mice were challenged with 10 × LD 50 of mouse-adapted pdm09 viruses, and percentage of body weight loss ( K ) and survival ( L ) were similarly monitored daily for 14 days. n = 8–9 in A – C , n = 5–10 in D – F , n = 5 in G – I , and n = 8 in J – L . One-way ANOVA with Newman-Keuls multiple-comparison test was used to compare differences between groups ( A – D , G , and J ). Log-rank test with Bonferroni’s correction was used to compare differences of survival between LPD and ID groups ( F , I , and L ). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

    Article Snippet: After washing in PBS supplemented with 0.05% Tween 20 (PBST), HRP-conjugated anti-mouse IgG (NA931, GE Healthcare Life Sciences, now Cytiva) or subtype IgG1 (046120, Invitrogen, Thermo Fisher Scientific), IgG2a (NB7516, Novus Biologicals), or IgG2c antibodies (A90-136P, Bethyl Laboratories) were added and incubated at room temperature for 1 hour.

    Techniques: Adjuvant, HI Assay, Comparison

    WT and MyD88-KO mice were subjected to AFL or sham treatment followed by ID injection of 0.3 μg pdm09 vaccine into AFL- or sham-treated skin. Serum HI titer ( A ), and anti-rHA IgG ( B ) and subtype IgG1 ( C ) and IgG2c antibody titers ( D ) were measured 3 weeks later. n = 9–11. One-tailed Student’s t test was used to compare differences between groups. *, P < 0.05.

    Journal: JCI Insight

    Article Title: Vaccine delivery alerts innate immune systems for more immunogenic vaccination

    doi: 10.1172/jci.insight.144627

    Figure Lengend Snippet: WT and MyD88-KO mice were subjected to AFL or sham treatment followed by ID injection of 0.3 μg pdm09 vaccine into AFL- or sham-treated skin. Serum HI titer ( A ), and anti-rHA IgG ( B ) and subtype IgG1 ( C ) and IgG2c antibody titers ( D ) were measured 3 weeks later. n = 9–11. One-tailed Student’s t test was used to compare differences between groups. *, P < 0.05.

    Article Snippet: After washing in PBS supplemented with 0.05% Tween 20 (PBST), HRP-conjugated anti-mouse IgG (NA931, GE Healthcare Life Sciences, now Cytiva) or subtype IgG1 (046120, Invitrogen, Thermo Fisher Scientific), IgG2a (NB7516, Novus Biologicals), or IgG2c antibodies (A90-136P, Bethyl Laboratories) were added and incubated at room temperature for 1 hour.

    Techniques: Injection, One-tailed Test